• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Derm In The News: May 19-25


Keep up with the latest headlines in dermatology from the past week, including exposure to UV light and its implications for metabolism, the effects of skin conditions on children, and more.

Neuroscience News: UV Light Increases Appetite But Suppresses Weight Gain

A recent study published in the Journal of Investigative Dermatology has found that exposure to ultraviolet (UV) light can increase appetite while preventing weight gain by affecting hormones and neurotransmitters. Researchers observed that UV exposure in mice led to decreased leptin levels and increased norepinephrine, promoting energy expenditure and preventing weight gain even with increased appetite. Future research will focus on developing safe methods to replicate the beneficial effects of UV exposure without its adverse impacts.

Northwestern University: Children With Skin Diseases Suffer Stigma, Bullying and Depression

A Northwestern Medicine study, published in JAMA Dermatology, is the first large-scale research examining mental health issues in children with chronic skin conditions. The study found that many children and teens with conditions like acne, eczema, psoriasis, alopecia areata, and vitiligo experience significant stigma and bullying, leading to depression, anxiety, and poor peer relationships. The study, involving 1,671 children and 31 sites, revealed that 73% had experienced stigma, which was linked to a poor quality of life. Researchers also discovered a discrepancy between how children and doctors rated the severity and visibility of the disease.

Business Wire: Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab

Bristol Myers Squibb announced that the FDA has set a new Prescription Drug User Fee Act goal date of December 29, 2024, for the Biologics License Application for the subcutaneous formulation of Opdivo (nivolumab), combined with Halozyme’s recombinant human hyaluronidase. This application covers all approved adult solid tumor indications for Opdivo, either as monotherapy or in combination with other treatments.

Dermatology Times covered this news! Read more here.

L’Oréal: L’Oréal accelerates Beauty Tech leadership with advanced bioprinted skin technology and gen AI content lab to augment creativity

At Viva Technology Paris 2024, L’Oréal will present several innovations under the theme 'Beauty for Each, Powered by Beauty Tech,' emphasizing personalized, inclusive, and responsible beauty. These innovations include advanced skin and hair diagnostics, a GenAI-powered personal beauty assistant, the CREAITECH GenAI Beauty Content Lab to enhance creativity, an infrared light hair dryer, a micro-resurfacing skin care device, and a realistic bioprinted skin platform for research and product testing. The new bioprinted skin technology mimics diverse human skin conditions.

Wall Street Journal: Influencers Are Saying Sunscreen Causes Cancer. They Are Wrong.

Influencers on TikTok have recently been promoting dangerous health trends, including abandoning sunscreen due to fears about cancer-causing chemicals like benzene. These influencers claim, without evidence, that sunlight does not cause skin cancer and suggest alternatives like coconut oil for sun protection. Dermatology experts have led the conversation against these claims, educating and that the benefits of using sunscreen far outweigh any potential risks.

Have you seen any dermatology headlines this week that we may have missed? Share with us by emailing our team at DTEditor@mmhgroup.com.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.